)
Visual
test
Guard Therapeutics Intl
Guard Therapeutics Intl (GUARD) investor relations material
Guard Therapeutics Intl Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary20 Feb, 2026
Executive summary
Negative topline results from the phase 2b POINTER study led to the termination of the RMC-035 clinical program, marking a significant setback and prompting a strategic review, including potential merger or reverse acquisition options.
The company initiated cost-saving measures, scaled down operations, and began winding down all RMC-035-related activities.
After the reporting period, the company joined a European research consortium to evaluate GTX peptides for Alport's disease.
Financial highlights
Net sales for both Q4 and the full year 2025 were 0 KSEK (0 KSEK in 2024).
Net loss for Q4 was -16,330 KSEK (vs. -25,958 KSEK in Q4 2024); full-year net loss was -108,851 KSEK (vs. -96,066 KSEK in 2024).
Earnings per share for the year were -6.04 SEK (-8.62 SEK in 2024).
Cash and cash equivalents at year-end were 49,826 KSEK (54,186 KSEK in 2024).
Operating loss for the year was -107,195 KSEK (-99,905 KSEK in 2024), mainly due to R&D expenses.
Outlook and guidance
The strategic review is ongoing, with a focus on merger or reverse acquisition, expected to conclude in Q1 2026.
Available cash is considered sufficient to fund operations through 2026.
Prioritize strategic alternatives
GTX platform's path to market
Post-RMC-035 burn rate outlook
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Guard Therapeutics Intl
- Negative POINTER study results prompt strategic review and development pause.GUARD
Q3 202513 Nov 2025 - Phase 2b POINTER showed no significant kidney benefit for RMC-035, prompting strategic review.GUARDStudy Result27 Oct 2025
- Phase 2B kidney trial nears results, with strong data and major partnering discussions ongoing.GUARDDNB Carnegie Småbolagsdag1 Sep 2025
- Phase 2b POINTER study recruitment completed early; positive safety review and SEK 120M raised.GUARDQ2 202521 Aug 2025
- Phase 2b POINTER study underway; RMC-035 targets $1B+ global market in cardiac surgery.GUARDQ3 202413 Jun 2025
- Regulatory progress and new funding position Guard Therapeutics for key clinical milestones.GUARDQ2 202413 Jun 2025
- Q1 saw rapid clinical progress and SEK 120m in new funding, despite a widened loss.GUARDQ1 20256 Jun 2025
- Net loss widened as R&D ramped up for POINTER; major capital raise planned for 2025 milestones.GUARDQ4 20245 Jun 2025
Next Guard Therapeutics Intl earnings date
Q1 202611 May, 2026
Guard Therapeutics Intl
Next Guard Therapeutics Intl earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage